Pfizer Revenue 2006-2019 | PFE

Pfizer annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Pfizer revenue for the quarter ending June 30, 2019 was $13.264B, a 1.5% decline year-over-year.
  • Pfizer revenue for the twelve months ending June 30, 2019 was $53.657B, a 0.78% increase year-over-year.
  • Pfizer annual revenue for 2018 was $53.647B, a 2.1% increase from 2017.
  • Pfizer annual revenue for 2017 was $52.546B, a 0.53% decline from 2016.
  • Pfizer annual revenue for 2016 was $52.824B, a 8.13% increase from 2015.
Pfizer Annual Revenue
(Millions of US $)
2018 $53,647
2017 $52,546
2016 $52,824
2015 $48,851
2014 $49,605
2013 $51,584
2012 $54,657
2011 $61,035
2010 $65,165
2009 $49,269
2008 $48,296
2007 $48,418
2006 $48,371
2005 $47,405
Pfizer Quarterly Revenue
(Millions of US $)
Q2 2019 $13,264
Q1 2019 $13,118
Q4 2018 $13,977
Q3 2018 $13,298
Q2 2018 $13,466
Q1 2018 $12,906
Q4 2017 $13,703
Q3 2017 $13,168
Q2 2017 $12,896
Q1 2017 $12,779
Q4 2016 $13,627
Q3 2016 $13,045
Q2 2016 $13,147
Q1 2016 $13,005
Q4 2015 $14,047
Q3 2015 $12,087
Q2 2015 $11,853
Q1 2015 $10,864
Q4 2014 $13,118
Q3 2014 $12,361
Q2 2014 $12,773
Q1 2014 $11,353
Q4 2013 $13,558
Q3 2013 $12,643
Q2 2013 $12,973
Q1 2013 $12,410
Q4 2012 $12,851
Q3 2012 $12,953
Q2 2012 $13,968
Q1 2012 $14,885
Q4 2011 $11,439
Q3 2011 $16,609
Q2 2011 $16,485
Q1 2011 $16,502
Q4 2010 $15,462
Q3 2010 $15,995
Q2 2010 $17,132
Q1 2010 $16,576
Q4 2009 $15,797
Q3 2009 $11,621
Q2 2009 $10,984
Q1 2009 $10,867
Q4 2008 $12,346
Q3 2008 $11,973
Q2 2008 $12,129
Q1 2008 $11,848
Q4 2007 $12,870
Q3 2007 $11,990
Q2 2007 $11,084
Q1 2007 $12,474
Q4 2006 $12,603
Q3 2006 $12,280
Q2 2006 $11,741
Q1 2006 $11,747
Q4 2005 $11,599
Q3 2005 $11,263
Q2 2005 $11,452
Q1 2005 $13,091
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.220B $53.647B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $344.174B 14.99
Roche Holding AG (RHHBY) Switzerland $241.683B 0.00
Merck (MRK) United States $212.562B 17.48
Novartis AG (NVS) Switzerland $197.737B 17.02
Novo Nordisk (NVO) Denmark $120.697B 21.33
AstraZeneca (AZN) United Kingdom $114.317B 22.12
Sanofi (SNY) France $111.209B 13.66
Eli Lilly (LLY) United States $108.824B 20.31
AbbVie (ABBV) United States $105.372B 8.44
GlaxoSmithKline (GSK) United Kingdom $102.412B 12.87
Bristol-Myers Squibb (BMY) United States $81.559B 11.57
Bayer (BAYRY) Germany $68.561B 9.99
H Lundbeck (HLUYY) Denmark $6.721B 9.70